Article

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors

2024-08-26

Abstract excerpt

<h4>ABSTRACT</h4> Cancer genomic studies have identified frequent mutations in subunits of the SWI/SNF chromatin remodeling complex including SMARCA4 in non-small cell lung cancer with a frequency of up to 33% in advanced stage disease, making it the most frequently mutated complex in lung cancer. We and others have identified SMARCA2 to be synthetic lethal to SMARCA4, indicating SMARCA2 is a high value therap...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4cd8a130-d6c5-5f57-9e62-bcd4cd853b48
DOI: 10.1101/2024.08.23.608456

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C InhibitorsDOI 10.1101/2024.08.23.608456Read

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersSemantic proximity Read

Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.Semantic proximity Read

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.Semantic proximity Read

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.Semantic proximity Read

[Research Progress on SMARCA4 Mutation Non-small Cell Lung Cancer].Semantic proximity Read

The role of SMARCA4 in lung cancerSemantic proximity Read

SMARCA4: Current status and future perspectives in non-small-cell lung cancerSemantic proximity Read

603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutationSemantic proximity Read

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerSemantic proximity Read

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivoSemantic proximity Read

Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023Semantic proximity Read